Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Stephen J. Schuster, MD: Tisagenlecleucel Promising in Relapsed/Refractory DLBCL

December 30, 2021


Dr. Schuster shares results from the global JULIET trial of the CAR T-cell therapy tisagenlecleucel in patients with relapsed/refractory diffuse large B-cell lymphoma – a patient population with the “greatest unmet need.”

Advertisement intended for health care professionals

Connect with us:

CURRENT ISSUE
November 2024

Advertisement intended for health care professionals

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals